Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Six Questions For McKinsey Executives On Pharma’s Digital Experience

Executive Summary

McKinsey & Co executives Vikas Bhadoria and Parag Patel, in an interview with Scrip, shared some key insights into pharma’s recent efforts around digitization and advanced analytics including the emergence of a Bayer site as a manufacturing ‘lighthouse’, Novartis’ Nerve Live platform and sales rep versus digital channel effectiveness.

You may also be interested in...



Slew Of Challenges Calls For Revised Biopharma Playbook

While not immune to the impact of a storm of macroeconomic pressures, pharma companies have pulled through before, and they’ll do it again. However, this time around, the economic, geopolitical and internal cost and revenue pressures are unique and weathering the near-term turbulence will call for smart investment strategies that not only focus on quality assets, but that update companies to take advantage of new digital opportunities.

Re-Configuring Pharma Operations Amid Pandemic Strains

Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.

McKinsey Execs On Expanding Pharma’s Digital Push, Lessons From Amazon

Two McKinsey & Company executives share their views on pharma’s digital trajectory, including the role of manufacturing ‘lighthouses’ and opportunities to deploy digital and analytical tools across the entire value chain for both innovator and generic firms. They see Amazon’s playbook on leveraging digital technology as holding some interesting lessons for pharma.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC124879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel